Neogen
NEOG
11.68
-0.28
-2.34%
Neogen
US · NEOG
#2579 by market cap
Listed 1970
11.68
-0.28
-2.34%
Live - 5344 symbols - heartbeat 141s ago
· 2026-10-08 08:29
Pre-market
11.41
-2.31%
After-hours
11.49
-1.63%
Overnight
11.68
0.00%
- Market cap
- 2.55B
- P/E (TTM)i
- -44.92
- P/Bi
- 1.22
- EPSi
- -0.04
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on NEOG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.39, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.72% YoY
Margins
- Gross margin
- 46.93%
- Operating margin
- -2.48%
- Net margin
- -0.91%
Key ratios & quality
- Altman Z-Scorei
- 1.39
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 414.19M | 418.17M | 468.46M | 527.16M | 822.45M | 924.20M | 894.70M | 870.40M |
| Gross profit | 191.92M | 196.28M | 215.06M | 243.01M | 405.96M | 463.90M | 421.40M | 408.50M |
| Selling & admin expenses | 111.02M | 114.01M | 124.64M | 167.35M | 342.40M | 382.80M | 402.00M | 411.70M |
| Research & development | 12.81M | 14.75M | 16.25M | 17.05M | 26.04M | 22.50M | 21.10M | 18.40M |
| Operating profit | 68.09M | 67.52M | 74.17M | 58.62M | 37.52M | 58.60M | -1.70M | -21.60M |
| Pretax profit | 72.96M | 72.31M | 75.27M | 60.21M | -22.04M | -14.30M | -1.13B | -9.00M |
| Tax | 12.78M | 12.83M | 14.39M | 11.90M | 828.00K | -4.90M | -41.10M | -1.10M |
| Net profit | 60.18M | 59.48M | 60.88M | 48.31M | -22.87M | -9.40M | -1.09B | -7.90M |
| Basic EPS | 1 | 1 | 1 | 0 | 0 | 0 | -5 | 0 |
| Diluted EPS | 0.57 | 0.56 | 0.57 | 0.45 | -0.12 | -0.04 | -5.03 | -0.04 |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Revenue | 225.50M | 209.19M | 224.69M | 211.20M | 225.30M | 222.80M |
| Gross profit | 92.90M | 94.97M | 106.68M | 99.00M | 107.80M | 105.50M |
| Selling & admin expenses | 99.90M | 105.94M | 107.50M | 98.50M | 99.80M | 100.80M |
| Research & development | 6.30M | 5.13M | 4.56M | 3.80M | 4.90M | 6.50M |
| Operating profit | -13.30M | -16.09M | -5.38M | -3.30M | 3.10M | -1.80M |
| Pretax profit | -631.20M | 43.81M | -20.36M | -20.30M | -12.10M | -14.90M |
| Tax | -19.00M | 7.47M | -4.44M | -3.30M | -800.00K | -3.00M |
| Net profit | -612.20M | 36.34M | -15.92M | -17.00M | -11.30M | -11.90M |
| Basic EPS | -3 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -2.82 | 0.17 | -0.07 | -0.08 | -0.05 | -0.05 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 449.53M | 537.41M | 591.45M | 626.80M | 585.93M | 589.23M | 576.90M | 604.60M |
| Cash & ST investments | 267.52M | 343.67M | 381.09M | 381.05M | 245.57M | 170.94M | 129.00M | 185.50M |
| Inventory | 85.99M | 95.05M | 100.70M | 122.31M | 133.81M | 189.27M | 190.80M | 144.30M |
| Total assets | 695.74M | 797.18M | 920.19M | 992.93M | 4.55B | 4.55B | 3.44B | 3.35B |
| Total current liabilities | 38.25M | 48.49M | 53.60M | 77.84M | 145.47M | 154.32M | 174.00M | 158.20M |
| Short-term debt | -- | -- | -- | -- | -- | 2.45M | 19.30M | -- |
| Long-term debt | -- | -- | -- | -- | 885.44M | 888.39M | 874.80M | 793.70M |
| Total liabilities | 57,841,000.00 | 72,005,000.00 | 79,815,000.00 | 105,555,000.00 | 1,420,215,000.00 | 1,404,691,000.00 | 1,372,600,000.00 | 1,253,100,000.00 |
| Total equity | 637.90M | 725.18M | 840.38M | 887.37M | 3.13B | 3.14B | 2.07B | 2.09B |
| Retained earnings | 419.25M | 478.72M | 539.60M | 587.91M | 565.04M | 555.62M | -536.40M | -544.30M |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Total current assets | 576.90M | 524.06M | 574.58M | 590.00M | 604.60M | 582.50M |
| Cash & ST investments | 129.00M | 138.88M | 145.34M | 159.90M | 185.50M | 172.00M |
| Inventory | 190.80M | 193.41M | 162.77M | 161.70M | 144.30M | 146.10M |
| Total assets | 3.44B | 3.38B | 3.36B | 3.36B | 3.35B | 3.30B |
| Total current liabilities | 174.00M | 146.21M | 147.05M | 150.60M | 158.20M | 149.50M |
| Short-term debt | 19.30M | -- | -- | -- | -- | -- |
| Long-term debt | 874.80M | 792.53M | 792.93M | 793.30M | 793.70M | 774.20M |
| Total liabilities | 1,372,600,000.00 | 1,259,507,000.00 | 1,255,465,000.00 | 1,256,600,000.00 | 1,253,100,000.00 | 1,216,800,000.00 |
| Total equity | 2.07B | 2.12B | 2.10B | 2.10B | 2.09B | 2.09B |
| Retained earnings | -536.40M | -500.09M | -516.01M | -533.00M | -544.30M | -556.20M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 63.84M | 85.88M | 81.09M | 68.04M | 41.03M | 35.30M | 58.20M | 83.20M |
| Depreciation & amortization | 17.62M | 18.40M | 21.04M | 24.13M | 90.47M | 121.20M | 125.70M | 121.90M |
| Free cash flow | 49.18M | 61.83M | 54.38M | 43.61M | -24.73M | -76.10M | -46.40M | 31.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -3.14M | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 41.69M | 66.27M | 75.60M | 44.47M | 163.24M | 170.60M | 129.00M | 185.50M |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Operating cash flow | 16.40M | 10.85M | 19.44M | 22.70M | 30.20M | 12.90M |
| Depreciation & amortization | 36.50M | 29.06M | 28.93M | 28.92M | 35.00M | 30.40M |
| Free cash flow | 300.00K | -13.15M | 7.78M | 11.07M | 26.20M | 4.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 129.00M | 138.88M | 145.34M | 159.90M | 185.50M | 172.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 10.05 | 8.73 | 7.78 | 5.59 | -1.14 | -0.30 | -41.88 | -0.38 |
| ROA %i | 9.16 | 7.97 | 7.09 | 5.05 | -0.82 | -0.21 | -27.33 | -0.23 |
| ROIC %i | 9.40 | 8.00 | 7.61 | 5.47 | 0.56 | 0.86 | -29.31 | 1.46 |
| 5-year avg ROE %i | 10.43 | 10.14 | 9.76 | 8.88 | 6.20 | 4.13 | -5.99 | -7.62 |
| EBIT margin %i | 16.44 | 16.15 | 15.83 | 11.12 | 4.12 | 6.39 | -118.65 | 5.58 |
| FCF / sales %i | 11.87 | 14.78 | 11.61 | 8.27 | -- | -- | -- | 3.67 |
| Current ratioi | 11.75 | 11.08 | 11.03 | 8.05 | 4.03 | 3.82 | 3.32 | 3.82 |
| Quick ratioi | 9.15 | 8.83 | 8.82 | 6.18 | 2.74 | 2.23 | 1.62 | 2.10 |
| Debt / assetsi | -- | -- | -- | -- | 19.44 | 19.58 | 25.96 | 23.72 |
| LT debt / equityi | -- | -- | -- | -- | 28.25 | 28.26 | 42.24 | 37.92 |
| Interest coveragei | -- | -- | -- | -- | 0.61 | 0.81 | -14.82 | 0.84 |
| Revenue CAGR (3Y) %i | 8.84 | 5.29 | 5.59 | 8.37 | 25.29 | 25.42 | 19.28 | 1.91 |
| Net income CAGR (3Y) %i | 18.07 | 10.74 | -1.21 | -7.06 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 32.57 | 10.60 | 4.11 | -3.93 | -- | -- | -- | -- |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| ROE %i | -41.88 | -39.71 | -25.25 | -25.57 | -0.38 | -2.67 |
| ROA %i | -27.33 | -26.47 | -16.26 | -16.47 | -0.23 | -1.68 |
| ROIC %i | -29.31 | -28.22 | -16.76 | -16.98 | 1.46 | -0.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -118.65 | -113.23 | -62.63 | -64.88 | 5.58 | -1.44 |
| FCF / sales %i | -- | -- | -- | 0.69 | 3.67 | 5.63 |
| Current ratioi | 3.32 | 3.58 | 3.91 | 3.92 | 3.82 | 3.90 |
| Quick ratioi | 1.62 | 1.90 | 1.89 | 1.97 | 2.10 | 2.06 |
| Debt / assetsi | 25.96 | 23.46 | 23.60 | 23.62 | 23.72 | 23.44 |
| LT debt / equityi | 42.24 | 37.41 | 37.68 | 37.73 | 37.92 | 37.11 |
| Interest coveragei | -14.82 | -14.46 | -8.33 | -8.92 | 0.84 | -0.23 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Food Safety is the largest reported line at 76.13% of revenue, across 3 reported segments.
- The next-largest line, Animal Safety, is a distant second at 27.26% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Food Safety76.13%
Animal Safety27.26%
Region
International51.16%
Domestic48.84%
Quote time 2026-10-08 08:29:31 · For reference only, not investment advice and not tailored to your situation.